Skip to main content

Table 2 Characteristics of patients with active disease at the time of sampling

From: Th17 expansion in granulomatosis with polyangiitis (Wegener's): the role of disease activity, immune regulation and therapy

Patient number Age (years) ANCA type Disease duration (months) Disease activity at time of sampling BVAS CRP (mg/L)
1 55 PR3 0 A, ENT, K, L 25 292
2 37 PR3 44 A, ENT 5 20
3 55 PR3 57 A, K, L 15 247
4 58 MPO 120 A, L 7 23
5 49 PR3 190 A, ENT, L 10 46
6 57 PR3 259 Ey, ENT 6 < 5
7 56 PR3 191 Ey 6 < 5
8 82 MPO 0 L 4 44
9 53 PR3 0 A, ENT, K, L 17 160
10 74 PR3 0 K 10 NA
11 69 PR3 9 ENT, K 14 211
12 41 MPO 0 A, ENT, K, S 17 44
13 58 MPO 0 ENT, K, S 14 116
14 70 MPO 0 A, ENT, K, L 19 188
15 53 PR3 15 Ey, K 12 12
16 24 PR3 9 A, Ey 3 16
17 40 MPO 33 ENT 6 < 5
18 41 MPO 284 K, L 12 < 5
  1. None of the patients received induction therapy at the time of sampling. PR3/MPO, proteinase-3/myeloperoxidase; this reflects anti-neutrophil-cytoplasmic antibodies specificity (ANCA) at the time of diagnosis. Organ involvement of patients with active disease at the time of sampling is depicted. A, arthritis (joints); BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ENT, ear-nose-throat; Ey, ophthalmologic manifestation of disease; K, kidney; L, lung; S, skin.